Wellington Management Co. LLP has recently announced that it has increased stake in Apellis Pharmaceuticals Inc (NASDAQ:APLS) by 127.59%. After grabbing 15.17 million shares, the institutional investor is now in possession of 8.5 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 12.80% having worth around $738.03 million. Moreover, EcoR1 Capital, LLC increased its share by 5.45 million to have a control over 10.9 million shares. And The Vanguard Group, Inc. raised its holdings to 68728.0 shares by acquiring 9.33 million shares or 7.88% of the stake.
Apellis Pharmaceuticals Inc (APLS) concluded trading on 12/14/23 at a closing price of $52.18, with 15.37 million shares of worth about $801.94 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -41.76% during that period and on Thursday the price saw a loss of about -17.02%. Currently the company’s common shares owned by public are about 110.77M shares, out of which, 96.83M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 206 times over the past 12 months. They bought 3,006,887 shares in 89 of the transactions. In 117 selling transactions, insiders dumped 1,952,265 shares.
Vanguard Health Care Fund, Vanguard Total Stock Market ETF, and Vanguard Small Cap Index Fund are the top 3 mutual funds which are holding stakes in Apellis Pharmaceuticals Inc Vanguard Health Care Fund is currently holding 5.89 million shares of worth totaling $286.84 million. The company recently came buying 1.79 million shares which brought its stake up to 4.97% of the company’s outstanding shares. Vanguard Total Stock Market ETF bought 22171.0 shares, after which its hold over company’s outstanding shares expand to 2.64%, leaving 3.13 million shares with the mutual fund that have a worth of about $152.36 million. Vanguard Small Cap Index Fund, after buying 2.58 million shares, have now control over 2.18% of the stake in the company. It holds 5348.0 shares of worth $125.6 million.
However, the stock later moved at a day high price of 53.29, or with a loss of -17.02%. Stock saw a price change of -18.52% in past 5 days and over the past one month there was a price change of 8.39%. Year-to-date (YTD), APLS shares are showing a performance of 0.91% which decreased to -2.14% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $19.83 but also hit the highest price of $94.75 during that period. The average intraday trading volume for Apellis Pharmaceuticals Inc shares is 2.42 million. The stock is currently trading -5.51% below its 20-day simple moving average (SMA20), while that difference is up 4.86% for SMA50 and it goes to -14.15% lower than SMA200.
Wellington Management Co. LLP acquired 15.17 million shares of Apellis Pharmaceuticals Inc having value of about $738.03 million. Data submitted at the U.S SEC by Wellington Management Co. LLP revealed that the firm now holds 8.5 million shares in the company valued at close to $443674486.42, or have control over 127.59% stake in the company. Apellis Pharmaceuticals Inc (NASDAQ: APLS) currently have 110.77M outstanding shares and institutions hold larger chunk of about 93.70% of that. Holding of mutual funds in the company is about 43.26% while other institutional holders and individual stake holders have control over 50.59% and 30.06% of the stake respectively.
The stock has a current market capitalization of $6.18B and its 3Y-monthly beta is at 0.91. It has posted earnings per share of -$5.25 in the same period. It has Quick Ratio of 3.76 while making debt-to-equity ratio of 1.94. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for APLS, volatility over the week remained 7.49% while standing at 5.94% over the month.
Analysts are in expectations that Apellis Pharmaceuticals Inc (APLS) stock would likely to be making an EPS of -$0.89 in the current quarter, while forecast for next quarter EPS is -$0.67 and it is -$1.63 for next year. For the current quarter EPS, analysts have given the company a lowest target -$1.16 which is -$0.56 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$1.5 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 24.72% while it is estimated to increase by 60.58% in next year. EPS is likely to grow at an annualized rate of 33.30% for next 5-years, compared to annual growth of -10.80% made by the stock over the past 5-years.
